Background: Results of recent molecular studies on malignant gliomas in adults showed that deletions within the short arm of chromosome 1 and/or the long arm of chromosome 19 identified a prognostically favorable subgroup of tumors that often respond to conventional chemotherapy. To determine if this association applies to pediatric malignant gliomas, we examined the correlation between 1p and 19q deletions and outcome in the cohort derived from the Children’s Cancer Group study 945, the largest randomized trial of such tumors completed to date. Methods: Archival histopathologic material yielded tissue of sufficient quality and quantity for genotyping in 121 specimens. Sections were examined histologically and targets that contained malignant glioma were isolated by microdissection and subjected to polymerase-chain-reaction-based amplification of microsatellite loci using fluorochrome-labeled primers, followed by capillary electrophoresis, and fluorescent fragment analysis. One hundred and seven specimens had 2 alleles for at least 1 of the 3 1p loci examined, and were therefore informative for determining loss of heterozygosity, defined as at least a twofold difference in fluorescence intensity between the paired allelic bands; 99 were informative at 19q. Results: Thirty-two tumors (29.9%) had loss of heterozygosity involving 1p, 27 (28%) involving 19q, and 13 involving both, an incidence consistent with previous reports involving adult malignant gliomas. However, outcome analyses of the entire cohort found no favorable association between 1p loss, 19q loss, or the combination, and survival. Subset analysis disclosed no association with outcome in either arm of the study (which compared efficacy of 2 chemotherapeutic regimens) or in subgroups stratified by age, tumor location, or tumor histology. Conclusion: In contrast to recent observations of adult malignant gliomas, deletions involving chromosomes 1p or 19q did not predict a survival advantage in this series of pediatric high-grade gliomas, which might indicate that frequencies of various histologic and molecular subtypes of malignant gliomas differ between children and adults, and supports further efforts to identify prognostic indicators relevant to pediatric gliomas.

Keywords:
Anaplastic oligoastrocytoma, Childhood, Glioblastoma, 1p deletions, Prognostic factors
1.
Bauman GS, Ino Y, Ueki K, et al: Allelic loss of chromosome 1p and radiotherapy plus chemotherapy in patients with oligodendrogliomas. Int J Radiat Oncol Biol Phys 2000;48:825–830.
2.
Bello MJ, Leone PE, Nebreda P, et al: Allelic status of chromosome 1 in neoplasms of the nervous system. Cancer Genet Cytogenet 1995;83:160–164.
3.
Bredel M, Pollack IF, Hamilton RL, James CD: Epidermal growth factor receptor expression and gene amplification in high-grade non-brainstem gliomas of childhood. Clin Cancer Res 1999;5:1786–1792.
4.
Boyett JB, Yates AJ, Gilles FH, et al: When is a high-grade astrocytoma (HGA) not a HGA? Results of a central review of 226 cases of anaplastic astrocytoma (AA), glioblastoma multiforme (GBM), and other-HGA (Oth-HGA) by five neuropathologists. Proc Am Soc Clin Oncol 1998;17:526a.
5.
Burger PC, Minn AY, Smith JS, et al: Losses of chromosomes 1p and 19q in the diagnosis of oligodendroglioma. A study of paraffin-embedded sections. Mod Pathol 2001;14:842–853.
6.
Burger PC, Scheithauer BW, Vogel FS: Surgical Pathology of the Nervous System and Its Coverings, ed 3. New York, Churchill Livingstone, 1991.
7.
Cairncross JG, Ueki K, Zlatescu MC, et al: Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 1998;90:1473–1479.
8.
Campbell J, Pollack IF, Martinez AJ, Shultz BL: High-grade astrocytomas in children: Radiologically complete resection is associated with an excellent long-term prognosis. Neurosurgery 1996;38:258–264.
9.
Cheng Y, Ng H-K, Zhang S-F, et al: Genetic alterations in pediatric high-grade astrocytomas. Hum Pathol 1999;30:1284–1290.
10.
Collins VP: Progression as exemplified by human astrocytic tumors. Semin Cancer Biol 1999;9:267–276.
11.
Duffner PK, Krischer JP, Burger PC, et al: Treatment of infants with malignant gliomas: The Pediatric Oncology Group experience. J Neurooncol 1996;28:245–256.
12.
Ellenberg L, McComb JG, Siegel SE, Stowe S: Factors affecting intellectual outcome in pediatric brain tumor patients. Neurosurgery 1987;21:638–644.
13.
Finlay JL, Boyett JM, Yates AJ, et al: Randomized phase III trial in childhood hig-grade astrocytoma comparing vincristine, lomustine, and prednisone with the eight-drugs-in-1-day regimen. J Clin Oncol 1995;13:112–123.
14.
Finkelstein SD, Sasatomi E, Swalsky PA, Woods J, Lieberman F: Microdissection-based genotyping for optimal molecular diagnosis and prognostication of human gliomas. Neurooncology 2000;2:261.
15.
Finkelstein SD, Sayegh R, Christensen S, Swalsky PA: Genotypic classification of colorectal adenocarcinoma. Biologic behavior correlates with K-ras-2 mutation type. Cancer 1993;71:3827–3838.
16.
Galanis E, Buckner J, Kimmel D, et al: Gene amplification of a prognostic factor in primary and secondary high-grade malignant gliomas. Int J Oncol 1998;13:717–724.
17.
He J, Olson JJ, James CD: Lack of p16INK4 or retinoblastoma protein (pRb), or amplification-associated overexpression of cdk4 is observed in distinct subsets of malignant glial tumors and cell lines. Cancer Res 1995;55:4833–4836.
18.
Ino Y, Betensky RA, Zlatescu MC, et al: Molecular subtypes of anaplastic oligodendroglioma: Implications for patient management at diagnosis. Clin Cancer Res 2001;7:839–845.
19.
Ino Y, Zlatescu MC, Sasaki H, et al: Long survival and therapeutic responses in patients with histologically disparate high-grade gliomas demonstrating chromosome 1p loss. J Neurosurg 2000;92:983–990.
20.
Kraus JA, Lamszus K, Glesmann N, et al: Molecular genetic alterations in glioblastomas with oligodendroglial component. Acta Neuropathol 2001;101:311–320.
21.
Louis DN: A molecular genetic model of astrocytoma histopathology. Brain Pathol 1997;7:755–764.
22.
Maintz DD, Fiedler K, Koopman J, et al: Molecular genetic evidence for subtypes of oligoastrocytomas. J Neuropathol Exp Neurol 1997;56:1098–1104.
23.
Mason WP, Grovas A, Halpern S, et al: Intensive chemotherapy and bone marrow rescue for young children with newly diagnosed malignant brain tumors. J Clin Oncol 1998;16:210–221.
24.
Moore BD 3rd, Ater JL, Copeland DR: Improved neuropsychological outcome in children with brain tumors diagnosed during infancy and treated without cranial irradiation. J Child Neurol 1992;7:281–290.
25.
Pollack IF: Current concepts: Brain tumors in children. N Engl J Med 1994;331:1500–1507.
26.
Pollack IF, Finkelstein SD, Burnham J, et al: Age and TP53 mutation frequency in childhood malignant gliomas: Results in a multi-institutional cohort. Cancer Res 2001;61:7404–7407.
27.
Pollack IF, Finkelstein SD, Woods J, et al: Expression of p53 and prognosis in children with malignant gliomas. N Engl J Med 2002;346:420–427.
28.
Pollack IF, Hamilton RL, Burnham J, et al: Impact of proliferation index on outcome in childhood malignant gliomas: Results in a multi-institutional cohort. Neurosurgery 2002;50:1238–1244.
29.
Pollack IF, Hamilton RL, Finkelstein SD, et al: The relationship between TP53 mutations and overexpression of p53 and prognosis in malignant gliomas of childhood. Cancer Res 1997;57:304–309.
30.
Radcliffe J, Packer RJ, Atkins TE, et al: Three- and four-year cognitive outcome in children with noncortical brain tumors treated with whole-brain radiotherapy. Ann Neurol 1992;32:551–554.
31.
Raffel C, Frederick L, O’Fallon JR, et al: Analysis of oncogene and tumor suppressor gene alterations in pediatric malignant astrocytomas reveals reduced survival for patients with PTEN mutations. Clin Cancer Res 1999;5:4085–4090.
32.
Sasaki H, Zlatescu MC, Betensky RA, et al: Histopathological-molecular genetic correlations in referral pathologist-diagnosed low-grade ‘oligodendroglioma’. J Neuropathol Exp Neurol 2002;61:58–63.
33.
Schmidt MC, Antweiler S, Urban N, et al: Impact of genotype and morphology on the prognosis of glioblastoma. J Neuropathol Exp Neurol 2002;61:321–328.
34.
Smith JS, Alderete B, Minn Y, et al: Localization of common deletion regions on 1p and 19q in human gliomas and their association with histological subtype. Oncogene 1999;18:4144–4152.
35.
Sposto R, Ertel IJ, Jenkin RDT, et al: The effectiveness of chemotherapy for treatment of high-grade astrocytoma in children: Results of a randomized trial. J Neurooncology 1989;7:165–177.
36.
Sung T, Miller DC, Hayes RL, Alonso M, Yee H, Newcombe EW: Preferential inactivation of the p53 tumor suppressor pathway and lack of EGFR amplification distinguish de novo high-grade pediatric astrocytomas from de novo adult astrocytomas. Brain Pathol 2000;10:249–259.
37.
Sure U, Ruedi D, Tachibana O, Yonekawa Y, Ohgaki H, Kleihues P, Hegi ME: Determination of p53 mutations, EGFR overexpression, and low of p16 expression in pediatric glioblastomas. J Neuropathol Exp Neurol 1997;56:782–789.
38.
von Deimling A, von Ammon K, Schoenfeld D, Weistler OD, Seizinger BR, Louis DN: Subsets of glioblastoma multiforme defined by molecular genetic analysis. Brain Pathol 1993;3:19–26.
39.
Watanabe K, Tachibana O, Sato K, Yonekawa Y, Kleihues P, Ohgaki H: Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas. Brain Pathol 1996;6:217–224.
40.
Wooten EC, Fults D, Duggirala R, et al: A study of loss of heterozygosity at 70 loci in anaplastic astrocytoma and glioblastoma multiforme with implications for tumor evolution. Neurooncol 1999;1:169–176.
© 2003 S. Karger AG, Basel
2003
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.